Comparative Pharmacology
Head-to-head clinical analysis: STELAZINE versus TRILAFON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STELAZINE versus TRILAFON.
STELAZINE vs TRILAFON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.
Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.
Adults: 2-10 mg orally twice daily; maximum 40 mg/day.
8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours (up to 40 hours in chronic use). Clinical context: Steady-state is reached in 5-7 days; allows once- or twice-daily dosing.
Terminal elimination half-life is approximately 10–20 hours (mean ~12 hours); supports twice-daily dosing.
Primarily renal (metabolites and unchanged drug; ~50% as metabolites); biliary/fecal excretion accounts for <20%.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for the majority of elimination.
Category C
Category C
Phenothiazine Antipsychotic
Phenothiazine Antipsychotic